Maridebart Cafraglutide
MARITIME-OSA-1
Amgen · Phase 3 · Active, not recruiting · Enrollment 250
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Maridebart Cafraglutide | Obesity or overweight | n/r | n/r | n/r | n/r |
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |